Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
27 Aug 24
8-K
Departure of Directors or Certain Officers
26 Aug 24
8-K
Eliem Therapeutics Reports Second Quarter Financial Results
14 Aug 24
10-Q
2024 Q2
Quarterly report
14 Aug 24
EFFECT
Notice of effectiveness
24 Jul 24
424B3
Prospectus supplement
23 Jul 24
S-3
Shelf registration
12 Jul 24
D
$120.00 mm in equity, sold $120.00 mm, 8 investors
2 Jul 24
D
$41.87 mm in equity, sold $41.87 mm, 6 investors
2 Jul 24
8-K
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
27 Jun 24
8-K
Submission of Matters to a Vote of Security Holders
26 Jun 24
DEFA14A
Additional proxy soliciting materials
14 Jun 24
DEFA14A
Additional proxy soliciting materials
12 Jun 24
8-K
Departure of Directors or Certain Officers
12 Jun 24
ARS
2023 FY
Annual report to shareholders
4 Jun 24
DEFM14A
Proxy related to merger
4 Jun 24
PREM14A
Preliminary proxy related to merger
17 May 24
10-Q
2024 Q1
Quarterly report
15 May 24
10-K/A
2023 FY
Annual report (amended)
29 Apr 24
DEFA14A
Additional proxy soliciting materials
11 Apr 24
8-K
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
11 Apr 24
S-8
Registration of securities for employees
28 Mar 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Other Events
18 Mar 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Eliem Therapeutics Announces Plans to Explore Strategic Alternatives
20 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
19 May 23
8-K
Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights
11 May 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
6 Apr 23
DEFA14A
Additional proxy soliciting materials
6 Apr 23
DEF 14A
Definitive proxy
6 Apr 23
8-K
Departure of Directors or Certain Officers
16 Mar 23
S-8
Registration of securities for employees
6 Mar 23
8-K
Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights
6 Mar 23
10-K
2022 FY
Annual report
6 Mar 23
8-K
Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition
13 Feb 23
8-K
Departure of Directors or Certain Officers
24 Jan 23
8-K
Departure of Directors or Certain Officers
20 Dec 22
Latest ownership filings
4
Emily Pimblett
20 Sep 24
4
Brett Kaplan
26 Aug 24
3
Brett Kaplan
26 Aug 24
SC 13D/A
AI ETI LLC
16 Aug 24
SC 13G/A
Affinity Asset Advisors, LLC
14 Aug 24
4
Valerie Morisset
23 Jul 24
4
Valerie Morisset
19 Jul 24
4
Valerie Morisset
17 Jul 24
4
Valerie Morisset
16 Jul 24
4
Valerie Morisset
11 Jul 24
4
Valerie Morisset
9 Jul 24
4
Valerie Morisset
3 Jul 24
SC 13G
Deep Track Capital, LP
2 Jul 24
4
Peter Kolchinsky
1 Jul 24
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
1 Jul 24
4
Peter Kolchinsky
28 Jun 24
4
Andrew David Levin
28 Jun 24
4
Adam Joseph Rosenberg
28 Jun 24
4
Judith Dunn
28 Jun 24
4
Simon Tate
28 Jun 24
4
Liam Ratcliffe
28 Jun 24
4
Aoife Brennan
27 Jun 24
4
Stephen Basil Thomas
27 Jun 24
3
Stephen Basil Thomas
27 Jun 24
3
Aoife Brennan
27 Jun 24
4
Emily Pimblett
21 Jun 24
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
6 Jun 24
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
17 May 24
SC 13D/A
AI ETI LLC
17 May 24
SC 13G
Affinity Asset Advisors, LLC
7 May 24
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
12 Apr 24
4
Valerie Morisset
8 Apr 24
4
Emily Pimblett
20 Mar 24
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
18 Mar 24
4
Valerie Morisset
4 Mar 24
SC 13G/A
BML Investment Partners, L.P.
7 Feb 24
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
17 Nov 23
SC 13D/A
AI ETI LLC
13 Nov 23
4
Peter Kolchinsky
22 May 23
4
Simon Tate
22 May 23